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Summary
The integrin a9b1 is widely expressed on neutrophils,
smooth muscle, hepatocytes, endothelia, and some
epithelia. We now show that mice lacking this integrin
have a dramatic defect in neutrophil development,
with decreased numbers of granulocyte precursors
in bone marrow and impaired differentiation of bone
marrow cells into granulocytes. In response to granu-
locyte colony-stimulating factor (G-CSF), a9-deficient
bone marrow cells or human bone marrow cells in-
cubated with a9b1-blocking antibody demonstrated
decreased phosphorylation of signal transducer and
activator of transcription 3 and extracellular signal-
regulated protein kinase. These effects depended on
the a9 subunit cytoplasmic domain, which was re-
quired for formation of a physical complex between
a9b1 and ligatedG-CSF receptor. Integrin a9b1was re-
quired for granulopoiesis and played a permissive role
in the G-CSF-signaling pathway, suggesting that this
integrin could play an important role in disorders of
granulocyte development and other conditions char-
acterized by defective G-CSF signaling.
Introduction
Integrins are transmembrane heterodimers that partici-
pate in the translation of spatially fixed extracellular
signals into a wide variety of changes in cell behavior
(Hynes et al., 1999). Members of this family share com-
mon functions (e.g., cell attachment, spreading, and sur-
vival) and utilize a number of common signaling interme-
diates (e.g., the focal adhesion kinase and src family
kinases) (Clark and Brugge, 1995; Hynes, 1992). How-
ever, the diverse and largely nonoverlapping pheno-
types of mice expressing null alleles of individual integ-
rin subunit genes underscores the biological importance
of integrin specificity (Hynes and Bader, 1997; Shep-
pard, 2000).
The phenotype of a9-deficient mice provided strong
evidence that a9b1 plays a unique and nonredundant
role in vivo. These mice survive embryonic development
normally, but all die by 12 days of age from respiratory
failure (Huang et al., 2000). The presence of bilateral chy-
*Correspondence: dean.sheppard@ucsf.edulothorax suggested a defect in lymphatic development
in these animals.
The integrin a9b1 is widely expressed in airway epi-
thelium; smooth, skeletal, and cardiac muscle cells;
hepatocytes; and neutrophils (Palmer et al., 1993). Mul-
tiple ligands have been identified for this integrin, includ-
ing the inducible endothelial counter-receptor, vascular
cell adhesion molecule-1 (VCAM-1) (Taooka et al., 1999),
the extracellular matrix proteins tenascin C (Yokosaki
et al., 1994) and osteopontin (Smith et al., 1996; Yoko-
saki et al., 1999), some members of ADAMs family (a
disintegrin and metalloproteases) (Bridges et al., 2004;
Eto et al., 2002; Tomczuk et al., 2003), coagulation factor
XIII, and von Willebrand factor (Takahashi et al., 2000).
a9b1 is highly expressed on human neutrophils and is
critical for neutrophil migration on VCAM-1 and tenas-
cin-C (Taooka et al., 1999). However, the in vivo function
of a9b1 on neutrophils is not clear. Because of the early
postnatal mortality in a9-deficient mice, neither we nor
others have previously characterized the effects of
loss of this integrin on neutrophil function. By evaluating
peripheral blood and bone marrow from juvenile a9-
deficient mice, we now describe a dramatic defect in
granulocyte development in these animals. Character-
ization of this defect led us to the identification of a path-
way by which integrin a9b1 enhanced G-CSF-receptor
signaling and facilitated the effects of G-CSF on neutro-
phil development. These findings suggest a potentially
important role for the a9b1 integrin in diseases charac-
terized by defects in neutrophil development or other
abnormalities in G-CSF signaling.
Results
Integrin a9-Deficient Mice Have Defective
Granulopoiesis
Peripheral blood from a9-deficient mice and littermate
controls was stained for the presence of the neutrophil
cell-surface marker Gr-1 (Figure 1A). The percentage
of neutrophils was dramatically decreased in Itga92/2
mice (Figure 1B). There were no major differences in to-
tal white blood cells, platelets, lymphocytes, or eosino-
phils between Itga92/2, Itga9+/2, and Itga9+/+ mice (Fig-
ure 1B). The percentage of relatively mature myeloid
cells (metamyelocytes and granulocytes) and myelo-
cytes in bone marrow was also decreased in Itga92/2
mice. There were no differences in any other cell types
(Figure 1C). Integrin a9b1 is expressed on granulocytes
in human peripheral blood (Taooka et al., 1999). We con-
firmed (by immunoblotting) that a9b1 is also expressed
on murine bone marrow cells (Figure 1D). Expression
of a9b1 was also detected by flow cytometry on a subset
of human bone marrow cells (Figure 1E). Integrin a9b1 is
known contribute to cell adhesion and migration in vitro
(Taooka et al., 1999; Young et al., 2001). It was thus pos-
sible that the decreased number of neutrophils could be
due to redistribution. We therefore examined neutrophil
and metamyelocyte numbers in the spleen. Neutrophils
were 2% and metamyelocytes were 1% of total spleen
cells. There was no difference between integrin a9 null
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896Figure 1. a9-Deficient Mice Are Neutropenic
(A) Flow cytometry analysis of neutrophils in peripheral blood. Peripheral blood was collected from wild-type, Itga9+/2, and Itga92/2 mice,
stained with PE-conjugated anti-Gr-1, and analyzed by flow cytometry.
(B) Percentage of neutrophils in peripheral blood from wild-type, Itga9+/2, and Itga92/2mice (determined by Wright-Giemsa staining). Values are
means from at least six mice from each group. *p = 0.003 (Itga9+/2 versus Itga92/2).
(C) Bone marrow analysis. Cell counts and differential counts were performed on cells recovered from six sex-matched littermates of each
genotype. *p = 0.002, **p = 1.1 3 1024 (Itga9+/+ versus Itga92/2).
(D) Expression of integrin a9b1 in mouse bone marrow cells. Lysates of bone marrow cells were blotted by a9 cytoplasmic domain antiserum
1057 (Palmer et al., 1993).
(E) Expression of integrin a9b1 in human bone marrow cells. Cells from human donor bone marrow were stained with anti-integrin a9b1, Y9A2.
Open peaks represent fluorescence (FL) of mouse IgG1 control-stained cells, and shaded peaks represent fluorescence of CHO cells stained
with Y9A2. Error bars denote the mean 6 SD.mice and controls, suggesting that the decrease in neu-
trophils in peripheral blood and bone marrow of a9 null
mice is not due to redistribution.
Integrin a9-Deficient Mice Have a Defect
in Granulocyte Differentiation
To determine whether the neutropenia in a9-deficient
mice could be a consequence of cytokine-signaling de-
fects in hematopoietic progenitors, we tested the in vitro
responses of bone marrow to a range of hematopoietic
growth factors. Responses to granulocyte macrophage
colony-stimulating factor (GM-CSF), macrophage col-
ony-stimulating factor (M-CSF), IL-3, IL-6, and stem
cell factor (SCF) were the same for bone marrow har-
vested from Itga92/2 and Itga9+/2 mice. However, inresponse to granulocyte colony-stimulating factor
(G-CSF), there was a selective decrease in both the
number of colonies formed (Figure 2A) and the number
of cells in each colony in Itga92/2 cells (Figure 2B). Integ-
rin a9 null bone marrow cells had decreased number of
colonies in response to range of concentration of G-CSF
(Figure 2C). Both wild-type and integrin a9 null colonies
contained 40%–50% mature neutrophils, suggesting
that loss of a9 does not lead to maturation arrest
(Figure 2D). This defect was partially rescued by restor-
ing the expression of a9 to bone marrow from Itga92/2
mice (Figure 2E).
To determine the significance of this pathway for hu-
man bone marrow cells and to exclude the possibility
that the abnormal response of a9-deficient mouse
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897Figure 2. a9-Deficient Bone Marrow Is Hyporesponsive to G-CSF
(A) Bone marrow cells were plated in methylcellulose-containing media supplemented with the indicated cytokine. Hematopoietic colonies
containing more than 30 cells were scored after 7–8 days. n = 7 for each genotype. *p = 5.6 3 1024.
(B) Cellular content of a9-deficient colonies relative to controls. 10–80 consecutive colonies from parallel cultures of bone marrow cells were
picked, pooled, and counted. Mean 6 SD of results from four to six mice per genotype. *p = 1.5 3 1023.
(C) Colony-forming assay for mouse bone marrow cells stimulated by G-CSF (0–100 ng/ml).
(D) Differential counts of bone marrow cells. Cells were collected from colony-forming assay. Black bars, neutrophils and bands; gray bars,
myelocytes and metamyelocytes; white bars, other cells.
(E) Mouse bone marrow cells were infected with a retrovirus expressing full-length, mature a9 (a9) or with empty vector (vector). Colony-forming
assays were performed with 20 ng/ml G-CSF. *p = 5 3 1023.
(F) Colony-forming assays with human bone marrow cells stimulated by a range of concentrations of G-CSF (0–20 ng/ml) in the presence of
integrin a9b1-blocking antibody Y9A2 (gray bars) or control normal mouse IgG (black bars). Error bars denote the mean 6 SD.bone marrow to G-CSF was simply due to a decreased
number of granulocyte precursors, we examined the ef-
fects of a blocking antibody to a9b1 on in vitro colony
formation with normal human bone marrow. Responses
to G-CSF were substantially attenuated in these cells by
treatment with the a9b1-blocking antibody Y9A2 (Fig-
ure 2F). Together, these results suggest that a9b1 con-
tributes to neutrophil development by specifically facili-
tating neutrophil differentiation in response to G-CSF.Integrin a9-Deficient Bone Marrow Cells Exhibit
Attenuated Signal Transducer and Activator of
Transcription 3 Activation in Response to G-CSF
To determine whether the reduced responsiveness to
G-CSF could be due to decreased expression of G-CSF
receptor in bone marrow cells from integrin a9 null mice,
we examined the surface expression of G-CSF receptor
on mouse bone marrow cells by incubation with labeled
G-CSF. There was no difference in receptor expression
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898Figure 3. G-CSF-Induced STAT3 Phosphorylation Is Attenuated by Loss or Blockade of Integrin a9b1
(A) Flow cytometry of G-CSF receptor expression on mouse bone marrow cells. Cells were incubated with PE-conjugated G-CSF (shaded peak)
or streptavidin-PE (open peak).
(B) Mean fluorescence intensity for G-CSF receptor expression (n = 3 for each genotype).
(C) Flow cytometry analysis of expression of G-CSF receptor and integrin a9 in human bone marrow mononuclear cells. Cells were incubated
with PE-conjugated anti-G-CSF receptor and biotinylated anti-a9b1 (Y9A2) or biotin mouse IgG1 control followed by incubation with FITC-
conjugated streptavidin. G-CSF receptor-positive and -negative cells were gated as light-shaded and dark-shaded peaks.
(D) STAT3 phosphorylation in mouse bone marrow cells. Bone marrow cells from a9-deficient or wild-type mice were treated with G-CSF for 5 or
10 min and analyzed by immunoblotting with anti-Phospho-STAT3 (Tyr705) or anti-total STAT3.
(E) STAT3 phosphorylation of human bone marrow cells incubated with a9b1-blocking antibody (Y9A2) or control antibody for 30 min followed by
G-CSF treatment. Error bars denote the mean 6 SD.between integrin a9 null mice and controls (Figures 3A
and 3B).
To determine whether the impaired responsiveness to
G-CSF could be explained by interaction between a9b1
and the G-CSF-signaling pathway, we first examined
whether a9b1 and the G-CSF receptor were expressed
in the same cells. Flow cytometry showed that the
majority of human bone marrow cells that express the
G-CSF receptor also express a9b1 (Figure 3C). To as-
sess the ability of the a9-deficient bone marrow cellsto produce the signals immediately downstream of the
G-CSF receptor, we stimulated bone marrow with
G-CSF and evaluated activation of the proximal signal-
ing intermediate, STAT3 (signal transducer and activator
of transcription 3). As expected, STAT3 phosphoryla-
tion was readily observed 5 min and 30 min after G-CSF
stimulation of Itga9+/+ bone marrow cells. However, this
effect was markedly reduced in a9-deficient bone mar-
row cells (Figure 3D). Similarly, STAT3 phosphorylation
was decreased in human bone marrow treated with
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899Figure 4. G-CSF-Induced STAT3 Phosphorylation Depends on Specific Sequences in the a9 Cytoplasmic Domain
(A) Cells were treated with a9b1-blocking antibody, Y9A2, or control IgG and plated on either an irrelevant ligand (collagen) or on collagen and an
a9b1-specific ligand (Tnfn3RAA) and were either untreated or treated with G-CSF for 5 or 30 min. Lysates were evaluated by immunoblotting with
anti-Phospho-STAT3 (Tyr705) or anti-total STAT3.
(B) Flow cytometry of G-CSF receptor expression on transfected CHO cells. Open peaks represent fluorescence (FL) of unstained CHO cells, and
shaded peaks represent fluorescence of CHO cells stained with the anti-G-CSF receptor.
(C) CHO cells expressing either G-CSF receptor alone, integrin a9b1 alone, or both G-CSF receptor and integrin a9b1 were plated on either
5 mg/ml Tnfn3RAA or fibronectin after incubation with or without a9b1 mAb, Y9A2. Adherent cells were stained with crystal violet and quantified
by measurement of absorbance at 595 nm (Young et al., 2001).
(D) STAT3 phosphorylation in response to G-CSF in CHO cells expressing G-CSF receptor and wild-type integrin a9 or a9 chimeras.
(E) STAT3 phosphorylation in response to G-CSF in CHO cells expressing the G-CSF receptor and full-length integrin a9 or a9 deletion mutants.
(F) STAT3 phosphorylation in response to G-CSF in CHO cells expressing G-CSF receptor and integrin a9. Cells were plated on collagen or
collagen and human recombinant VCAM-1-coated dishes. Error bars denote the mean 6 SD.integrin a9b1-blocking antibody (Figure 3E). These re-
sults suggest that expression of a9b1 does not affect
G-CSF receptor expression, but enhances downstream
STAT3 signaling in response to receptor ligation.
The Cytoplasmic Domain of Integrin a9 Is Critical
for Enhancement of G-CSF Signaling
To further elucidate the role of the integrin a9 subunit in
G-CSF signaling, we stably expressed the G-CSF recep-
tor and the integrin a9 subunit (and thus a9b1) in CHO
cells. Cotransfected CHO cells were stimulated with
G-CSF while plated on collagen (an adhesive substrate
that is not a ligand for a9b1) or on both collagen and
Tnfn3RAA (an integrin a9b1-specific ligand) (Yokosaki
et al., 1998). G-CSF-induced STAT3 phosphorylationwas markedly reduced in cells plated on collagen alone,
suggesting that ligation of integrin a9b1 is required for
enhancement of G-CSF signaling (Figure 4A). G-CSF-
induced phosphorylation of STAT3 was also markedly
inhibited by a9b1-blocking antibody (Y9A2), as we saw
in human bone marrow cells (Figure 4A).
To determine whether the cytoplasmic domain of the
a9 subunit specifically enhances G-CSF signaling, chi-
meric a subunits composed of the extracellular and
transmembrane domain of a9 fused to the cytoplasmic
domain of either the integrin a5 or a4 subunit were
used (Young et al., 2001). CHO cell lines expressing
equal amounts of each a9 construct were transfected
to express the G-CSF receptor, and similar G-CSF re-
ceptor expression was confirmed by flow cytometry
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(A) G-CSF-stimulated STAT3 phosphorylation of BaF3 cells expressing human G-CSF receptor and integrin a9b1.
(B) G-CSF-stimulated ERK, STAT5, and Akt phosphorylation.
(C) G-CSF-stimulated STAT3, EKR, STAT5, and Akt phosphorylation of mouse bone marrow cells from wild-type and a9-deficient mice.
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901(Figure 4B). We also examined adhesion of these trans-
fected cell lines on Tnfn3RAA and the irrelevant ligand,
plasma fibronectin. As expected, integrin a9b1-express-
ing cells, but not mock transfectants, adhered to
Tnfn3AA, and all cell lines adhered equally well to fibro-
nectin (Figure 4C). There were no differences in mor-
phology or cell proliferation between these cell lines
(data not shown). G-CSF-induced phosphorylation of
STAT3 was dramatically decreased in cell lines express-
ing either chimeric a9 subunit (Figure 4D).
To identify the cytoplasmic sequences critical for en-
hancing G-CSF signaling, a series of a9 cytoplasmic do-
main deletion mutants were used (translation stop co-
don was introduced into a9 cDNA to generate different
lengths of mutated a9 protein: 984 aa, 990 aa, and
1003 aa; the full length of a9 is 1006 aa). These deletion
mutants were stably coexpressed with G-CSF receptor
in CHO cells, and the expression of G-CSF receptor
was similar in each line (Figure 4B). These mutants
were chosen, in part, to evaluate the potential signifi-
cance of two cytoplasmic proteins, spermine spermi-
dine acetyl transferase (SSAT) and paxillin, that we
have previously found to bind to the a9 cytoplasmic do-
main and influence a9b1-dependent effects on cell be-
havior (Chen et al., 2004; Liu et al., 2001; Young et al.,
2001). Both of these functional effects are lost for
a9(984X) but preserved for a9(990X), and interaction of
both paxillin and SSAT is preserved for a9(990X). How-
ever, both of these mutants demonstrated markedly
reduced G-CSF-induced STAT3 phosphorylation (Fig-
ure 4E). Only the C-terminal three amino acids of the
a9 cytoplasmic domain could be deleted without affect-
ing this response (Figure 4E). Thus, sequences within
the a9 cytoplasmic domain are critical for enhancement
of G-CSF signaling, but this response is not simply due
to association with paxillin or SSAT. These results sug-
gest that sequences within the a9 cytoplasmic domain
are critical for enhancement of G-CSF signaling, but
that this response is not simply due to association with
paxillin or SSAT.
Integrin a9b1 Enhances G-CSF Signaling
in Response to Naturally Occurring Ligand
Tnfn3RAA used in the above experiments is a recombi-
nant form of the third fibronectin type III repeat of
chicken tenascin-C containing an RGD to RAA mutation.
To verify that a natural ligand for integrin a9b1 has the
same function, we plated CHO cells on plates coated
with collagen alone or collagen and human recombinant
VCAM-1. Phosphorylation of STAT3 was enhanced in
CHO cells from VCAM-1-coated plates and was in-
hibited by antibody against integrin a9b1 (Figure 4F).
Integrin a9b1 Enhances G-CSF Signaling
in Hematopoietic Cells
CHO cells expressing integrin a9b1 and the G-CSF
receptor were convenient for examining the crosstalk
between them in a simple system. However, CHO cellsare nonhematopoietic cells. To confirm the relevance
of our findings to hematopoietic cells, we used a pre-B
cell line BaF3 expressing the G-CSF receptor. We
could not detect expression of integrin a9 in BaF3 cells
by reverse-transcript PCR or immunoblot (data not
shown). We thus infected BaF3 expressing the G-CSF
receptor with a retrovirus expressing either integrin a9
or a9a5. Cells expressing both the wild-type integrin
a9b1 and the G-CSF receptor demonstrated increased
phosphorylation of STAT3 in response to G-CSF,
whereas cells expressing the a9a5 chimera were no dif-
ferent than cells expressing the G-CSF receptor alone
(Figure 5A).
STAT3 has been reported as important for G-CSF-in-
duced proliferation and differentiation (McLemore et al.,
2001); however, observations in mice with a conditional
knockout of STAT3 suggested that STAT3 could be a
negative regulator of granulopoiesis (Lee et al., 2002).
Some studies suggest that other signaling molecules
might be more important in G-CSF-induced proliferation
and differentiation, such as ERK (extracellular signal-
regulated protein kinase) (Kamezaki et al., 2005), Akt,
and STAT5 (signal transducer and activator of transcrip-
tion 5) (Dong et al., 1998; Ilaria et al., 1999; Zhu et al.,
2004). We therefore studied the activation of ERK, Akt,
and STAT5 in integrin a9b1-expressing BaF3 cells.
Both the magnitude and duration of ERK phosphoryla-
tion were increased in a9b1-expressing cells (Figure 5B).
However, phosphorylation of Akt and STAT5 were un-
affected by expression of a9b1. To determine the rele-
vance of these findings to primary bone marrow cells,
we performed similar experiments with bone marrow
from wild-type and a9 null mice. ERK phosphorylation
was enhanced in cells expressing a9b1, whereas Akt
and STAT5 phosphorylation was unaffected by the pres-
ence of the integrin (Figure 5C).
Suppressor of cytokine signaling 3 (SOCS3) is an im-
portant negative regulator of G-CSF signaling. SOCS3
downregulates signaling by binding the phosphorylated
tyrosine 729 of the cytoplasmic domain of the G-CSF
receptor (Zhuang et al., 2005). To determine whether
a9b1 affects G-CSF signaling by modulating interac-
tions with SOCS3, we examined ERK activation in BaF3
cells expressing the integrin and a mutant G-CSF recep-
tor in which tyrosine 729 was changed to phenylalanine
(Y729F). This mutation has been shown to prevent the
interaction of the G-CSF receptor with SOCS3 (Hortner
et al., 2002; Zhuang et al., 2005). As has been previously
reported, the Y729F mutation enhanced G-CSF-induced
ERK phosphorylation, but this effect was still further
enhanced in cells expressing integrin a9b1 (Figure 5D).
Thus, the effects of a9b1 ligation of G-CSF-receptor sig-
naling are not likely due to inhibition of interactions with
SOCS3.
In approximately 20% of patients suffering from se-
vere congenital neutropenia (SCN), C terminus trun-
cated mutations are found in the G-CSF receptor (Dong
et al., 1995, 1997). These patients have an increased(D and E) G-CSF-stimulated ERK phosphorylation in BaF3 cells expressing G-CSF receptor mutants (Y729F and D715).
(F) Proliferation assay of BaF3 cells expressing wild-type or mutant G-CSF receptor. BaF3 cells were cultured in G-CSF (100 ng/ml) containing
medium. Viable cell number was determined by counting and trypan blue exclusion.
(G) Flow cytometry of G-CSF receptor expression (shaded peaks) in BaF3 cells expressing wild-type, Y729F, or D715 G-CSF receptor. Error bars
denote the mean 6 SD.
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902Figure 6. G-CSF-Induced G-CSF Receptor Phosphorylation and Association with Integrin a9b1
(A) CHO cells expressing G-CSF receptor and wild-type a9 or an a9a5 chimera were treated with a9-blocking antibody (Y9A2) or control IgG for
30 min, plated on Tnfn3RAA, and treated with G-CSF (20 ng/ml). Lysates were immunoprecipitated with a9b1 antibody A9A1, and precipitated
protein was detected with anti-G-CSF receptor or integrin b1 cytoplasmic domain antiserum (to monitor equal capture of a9b1).
(B) CHO cells expressing G-CSF receptor and full-length integrin a9 or a9 cytoplasmic domain deletion mutants were incubated on Tnfn3RAA in
the presence or absence of G-CSF, and lysates were analyzed as above.
(C) BaF3 cells expressing wild-type, Y729F mutant, orD715 mutant G-CSF receptor and full-length integrin a9 were incubated on Tnfn3RAA in the
presence or absence of G-CSF. Lysates immunoprecipitated with a9b1 antibody A9A1 and probed with anti-HA or anti-integrin a9 cytoplasmic
domain (to monitor equal capture of a9b1).
(D) CHO cells expressing G-CSF receptor and wild-type integrin a9 or an a9a5 chimera were treated by anti-a9b1 Y9A2 or control (IgG) and G-CSF
as described above. Cells were lysed and immunoprecipitated by G-CSF receptor antibody. Precipitated protein was probed with anti-phospho-
tyrosine or anti-G-CSF receptor (to monitor equal capture of G-CSF receptor).risk of developing acute myeloid leukemia (AML) (Dong
et al., 1997). G-CSF receptor truncated at 715 mutant
(D715) shows a hyperproliferative response to G-CSF
in vitro and increased phosphorylation of ERK (Ward
et al., 1999; Zhu et al., 2004). To determine whether
a9b1 ligation could modulate signaling mediated by
the membrane-proximal region of the G-CSF receptor,
we coexpressed the truncated D715 mutant and a9b1
in BaF3 cells and examined ERK phosphorylation
and proliferation in response to G-CSF. As previously
reported, cells expressing D715 had increases in
G-CSF-induced ERK phosphorylation (Figure 5E) and
increased rates of proliferation (Figure 5F), even in the
absence of integrin a9b1. However, expression of the
integrin did not further enhance ERK phosphorylation
or G-CSF-induced proliferation in these cells (Figures
5E and 5F). Expression of a9b1 increased G-CSF-
induced proliferation in cells expressing either the
wild-type or Y729F mutant. Flow cytometry demon-
strated similar amounts of expression of wild-type,
Y729F, and D715 G-CSF receptors in both wild-type
and a9b1-expressing BaF3 cells (Figure 5G) and simi-
lar amount of a9b1 in all of the a9b1-expressing cell
lines (data not shown). Taken together, these results
suggest that a9b1 modulates signaling through se-
quences in the distal region of the G-CSF receptor
cytoplasmic domain to enhance ERK and STAT3 activ-
ity without affected signals mediated by STAT5,
SOCS3, or Akt.In Response to G-CSF, Ligated Integrin a9b1
Physically Interacts with the G-CSF Receptor
and Enhances Its Phosphorylation
To determine whether a9b1 could physically interact
with the G-CSF receptor, we plated CHO cells express-
ing the G-CSF receptor and wild-type a9 or an a9a5
chimera on the a9b1-specific ligand Tn3fnRAA and
immunoprecipitated a9-containing complexes with the
nonblocking a9b1 antibody, A9A1. In cells treated with
G-CSF, but not in untreated cells, the G-CSF receptor
was detectable in immunoprecipitates of wild-type
a9b1, but not in immunoprecipitates containing the chi-
meric a9a5 subunit, despite equal capture of both integ-
rins as determined by immunoblot for the associated b1
subunit (Figure 6A). Formation of complexes containing
the G-CSF receptor and wild-type a9b1 clearly de-
pended on ligation of the integrin, since complex for-
mation was completely inhibited by the a9b1-blocking
antibody, Y9A2.
Two integrin a9 cytoplasmic domain deletion muta-
tions a9(984X) and a9(990X), which cannot enhance
G-CSF signaling, were also evaluated for ability to phys-
ically associate with the G-CSF receptor by coimmuno-
precipitation. Neither mutant appeared to associate with
the G-CSF receptor (Figure 6B). In contrast, the one de-
letion mutant that preserved enhancement of G-CSF
signaling (a9(1003X)) responded to G-CSF stimulation
by associating with the G-CSF receptor to the same ex-
tent as seen with full-length a9. To confirm that physical
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903association was an important determinant of enhanced
signaling, we also performed coimmunoprecipitation
experiments in lysates from untreated or G-CSF-stimu-
lated BaF3 cells expressing wild-type G-CSF receptor,
the Y729F mutant (for which a9b1 also enhances sig-
naling) or the D715 mutant (for which a9b1 does not
enhance signaling). As predicted, G-CSF treatment in-
duced coassociation of the integrin with both the wild-
type and Y729F mutants but not with the D715 mutant
(Figure 6C).
Tyrosine phosphorylation of the G-CSF receptor is an
important early step in G-CSF signaling. Phosphoryla-
tion of the G-CSF receptor was evaluated by immuno-
precipitation of the receptor followed by immunoblot-
ting with a phosphotyrosine antibody. In response to
G-CSF, the G-CSF receptor was phosphorylated in cells
expressing wild-type, full-length a9 but not in cells ex-
pressing the a9a5 chimera. Phosphorylation of the
G-CSF receptor was also inhibited by blocking antibody
to a9b1 (Figure 6D). Thus, a9b1 is recruited to a protein
complex containing the ligated G-CSF receptor, and
the presence of a9b1 in this complex enhances phos-
phorylation of the G-CSF receptor in response to
G-CSF.
Discussion
In this report, we describe a specific and dramatic de-
fect in development of neutrophils in mice lacking the
integrin a9 subunit. This phenotype appears to be ex-
plained by a role for the a9b1 integrin in enhancing sig-
naling through the G-CSF receptor, an effect that we
show depends on physical association of a9b1 with
the G-CSF receptor. Both enhancement of signaling
and receptor coassociation depend on specific se-
quences within the a9 subunit cytoplasmic domain.
The observation that an integrin can physically asso-
ciate with and specifically enhance signaling through
another cell surface receptor is not novel. Several integ-
rins have been shown to enhance signaling through
growth factor receptors, including receptors for plate-
let-derived growth factor (Baron et al., 2002; Schneller
et al., 1997), vascular endothelial growth factor (Soldi
et al., 1999), and epithelial growth factor (EGF)
(Moro et al., 1998, 2002). A similar interaction has been
described between a b1 integrin and the interleukin-3
receptor (Defilippi et al., 2005). In most of these cases,
coligation of the integrin and the growth factor receptor
leads to both enhancement in growth factor receptor
signaling and to physical coassociation of the two re-
ceptors. At least one example has been described
where ligation of an integrin, a5b1, induces tyrosine
phosphorylation of a growth factor receptor (the EGF re-
ceptor) that appears to be independent of growth factor
receptor ligation (Moro et al., 1998). Our data suggest
that cooperative interaction between ligated G-CSF re-
ceptors and a9b1 occurs at a step quite proximal to
the initiation of G-CSF signaling, since three early steps
in this pathway, phosphorylation of STAT3, ERK, and
phosphorylation of the G-CSF receptor itself, are clearly
enhanced by a9b1. However, in this case it does not ap-
pear that a9b1 signaling is itself sufficient to initiate
G-CSF signaling, since in the four cell systems we stud-
ied (human and murine bone marrow and transfectedCHO and BaF3 cells), neither enhanced STAT3 phos-
phorylation nor G-CSF receptor phosphorylation was
detected in the absence of exogenous G-CSF. Based
on our findings that coligation of the integrin and the
G-CSF receptor led to physical association of both re-
ceptors, and on our observations that each of three a9
subunit mutants that failed to promote coassociation
also failed to enhance G-CSF signaling, we speculate
that physical coassociation is critical for enhancement
of signaling.
The precise molecular mechanism(s) by which physi-
cal coassociation of integrins and other receptors pro-
mote enhanced signaling have not been determined.
Since G-CSF receptor phosphorylation is required for
association with STAT3 and its subsequent phosphory-
lation by activated Janus kinases (JAKs), it is likely that
enhanced phosphorylation of the G-CSF receptor is
a proximal step in enhancement of G-CSF signaling by
a9b1. Because the amount of G-CSF receptor phos-
phorylation is thought to be determined by the balance
of phosphorylation by activated JAKs and dephosphor-
ylation by receptor-associated phosphatases, we spec-
ulate that the activity or physical association of one or
more of these kinases or phosphatases is regulated
through a9b1.
Our data clearly demonstrate that the short a9 subunit
cytoplasmic domain is critical for both enhanced G-CSF
signaling and physical association between ligated
G-CSF receptor and a9b1. Integrin cytoplasmic domains
are highly divergent, but even the most closely related
a4 subunit cytoplasmic domain cannot substitute for
a9. These findings raise the possibility that one or
more cytoplasmic proteins could bind to the a9 cyto-
plasmic domain and mediate receptor coassociation
and enhancement of G-CSF receptor signaling. We
and others have previously identified two proteins that
interact with the a9 cytoplasmic domain, SSAT (Chen
et al., 2004) and paxillin (Liu et al., 2001; Young et al.,
2001). Both interactions are biologically important, since
binding to paxillin appears to be critical for prevention of
cell spreading in cells expressing a9b1 (Young et al.,
2001) and SSAT appears to be critical for a9b1-mediated
enhancement of cell migration (Chen et al., 2004). One of
the deletion mutants examined in the current study,
990X, retains the ability to interact with both proteins
and to mediate both inhibition of cell spreading and en-
hancement of cell migration. However, this mutant was
unable to mediate either enhanced G-CSF signaling or
receptor coassociation, suggesting that interactions
with paxillin and/or SSAT are not sufficient to explain
these effects. While we cannot exclude participation of
either or both of these proteins, it is clear that interac-
tions with more C-terminal sequences within the a9
cytoplasmic domain are also required.
Previous studies have identified residues in the G-CSF
receptor cytoplasmic domain involved in activation or
repression of downstream signaling intermediates. The
a9 cytoplasmic domain could modulate responses to
G-CSF by direct or indirect interactions with any of
these. For example, the membrane-proximal region of
the G-CSF receptor (proximal to amino acid 715) has
been shown to activate Akt and ERK and to enhance
proliferation in response to G-CSF (Zhu et al., 2004).
Our results, demonstrating no enhancement of Akt
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receptor and no enhancement of ERK phosphorylation
or proliferation by a9b1 in cells expressing the D715
truncation mutant G-CSF receptor, suggest that a9b1
ligation does not modulate responses mediated by
the membrane-proximal region of the receptor. Our
data also suggest that a9b1 does not increase G-CSF-
receptor signaling by inhibiting interactions with SOCS3,
since a9b1 still enhanced both ERK phosphorylation and
G-CSF-induced proliferation in cells expressing the
Y729F mutant, which cannot bind to SOCS3. Together,
these results suggest that a9b1 most likely enhances
STAT3 and ERK activation and neutrophil development
through interactions with regions of the distal G-CSF re-
ceptor cytoplasmic domain other than the Y729 SOCS3
binding site.
G-CSF has been reported to inhibit neutrophil apopto-
sis and therefore enhance neutrophil survival (Colotta
et al., 1992; Martin et al., 1995; Rex et al., 1995). One re-
cent report suggests that ligation of a9b1 also prevents
apoptosis and enhances survival (Ross et al., 2006). It
is thus conceivable that the effects we describe could
be explained by enhancement of neutrophil survival.
However, we have been unable to demonstrate any
effects of a9b1 on apoptosis or survival with bone mar-
row from a9-deficient mice or human bone marrow
treated with a9b1-blocking antibody (data not shown).
We therefore favor the hypothesis that a9b1 contributes
to increased circulating neutrophil numbers and in-
creased bone marrow colonies through enhancement
of effects on G-CSF-mediated proliferation, differentia-
tion, or both.
Our studies in CHO cells and human bone marrow
suggest that the effects of a9b1 on enhancing G-CSF
signaling might depend on integrin ligation. Multiple
a9b1 ligands have been identified, including VCAM-1
(Taooka et al., 1999), tenascin C (Yokosaki et al., 1994),
osteopontin (Smith et al., 1996; Yokosaki et al., 1999),
ADAMs proteases (Bridges et al., 2004; Eto et al.,
2002; Tomczuk et al., 2003), coagulation factor XIII,
and von Willebrand factor (Takahashi et al., 2000). There
are a number of extracellular matrix proteins expressed
by bone marrow stem cells and stromal cells in bone
marrow. VCAM-1 is expressed on stromal cells and
mediates cell adhesion of hematopoietic progenitor
cells (Simmons et al., 1992). Osteoponin and tenascin
C are also expressed in bone marrow (Seiffert et al.,
1998; Yamate et al., 1997). Osteoponin is a component
of the hematopoietic stem cell (HSC) niche, which plays
an important role in HSC migration and proliferation
(Nilsson et al., 2005). So far there are no reports that in-
activating any of these a9b1 ligands leads to defects in
granulopoiesis, which may be a consequence of redun-
dancy given the large number of known ligands. In our
studies, it appeared likely that bone marrow cells gener-
ate their own a9b1 ligands in vitro, since an antibody that
interferes with ligand binding had the same effect as
genetic absence or deletion of the integrin. Furthermore,
addition of exogenous a9b1 ligands to cultured bone
marrow cells did not further enhance the effects on
G-CSF receptor signaling caused by expression of the
integrin (data not shown).
Recent evidence suggests that G-CSF signals im-
portant effects on a number of cell types other thangranulocytes. For example, the G-CSF receptor is ex-
pressed on endothelial cells, where expression of the
adhesion receptors, E-selectin, vascular endothelial
cell adhesion molecule-1, and intracelleular adhesion
molecule-1 at the cell surface are increased in response
to G-CSF (Fuste et al., 2004). The G-CSF receptor is also
expressed on neurons, and G-CSF inhibits apoptosis of
mature neurons. G-CSF has been reported to inhibit
acute neuronal degeneration and to contribute to long-
term plasticity after cerebral ischemia (Schneider et al.,
2005). Although we have not examined effects in other
cell types, a9b1 is also widely expressed and we specu-
late that a9b1-mediated enhancement of G-CSF signal-
ing could contribute to effects of G-CSF at one or more
of these other sites.
In summary, we have identified a pathway by which
the integrin a9b1 dramatically enhances the response
of bone marrow precursors to G-CSF signaling and
thereby contributes to normal granulocyte develop-
ment. This pathway involves physical association of
a9b1 with the ligated G-CSF receptor and enhancement
of the G-CSF-signaling pathway, beginning at a step
proximal to receptor phosphorylation. Defects in this
pathway could contribute to the development of con-
genital neutropenia and might also be important at
other sites of G-CSF signaling.
Experimental Procedures
Cytokines, Reagents, and Antibodies
PE-conjugated anti-Gr1 and anti-G-CSF receptor were from BD Bio-
science (San Jose, CA). Antibody against phospho-STAT3 (Tyr705),
STAT3, phospho-ERK (Thr202/Ser204), ERK, phospho-STAT5
(Tyr694), STAT5, phospho-Akt (Ser473), Akt, HA, and phosphotyro-
sine mouse mAb were from Cell Signaling (Beverly, MA). The a9b1-
specific ligand Tnfn3RAA (Prieto et al., 1993; Yokosaki et al., 1994,
1998), a9 mouse monoclonal antibody Y9A2 (Wang et al., 1996),
A9A1 (Vlahakis et al., 2005), and rabbit polyclonal antibody 1057
(Palmer et al., 1993) were prepared in our laboratory. Purified normal
IgG was from Jackson Immunoresearch (West Grove, PA). Purified
mouse IgG1 and biotinylated mouse IgG1 control were from eBio-
science (San Diego, CA). Collagen was from Sigma-Aldrich
(St. Louis, MO). Goat polyclonal anti-G-CSF receptor was from R&D
Systems (Minneapolis, MN). Human G-CSF and polyclonal antibody
against integrin b1 was from Chemicon International (Temecula, CA).
Mouse cytokines G-CSF, GM-CSF, IL-3, IL-6, and SCF were from
Stem Cell Technologies (Vancouver, Canada).
Animal Husbandry
Mice maintained on a C57/BL6 background were housed at the
animal care facility at the University of California, San Francisco,
and all studies were approved by the institutional review board. In-
tegrin a9b1 null mice were used for analysis between 6 and 7 days
after birth.
Murine Bone Marrow Analysis
Marrow was removed from femurs and tibias by flushing with PBS
buffer. The cell pellet was incubated with red blood cell lysis buffer,
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal calf serum, and captured on glass slides by cytospin.
Slides were stained with Wright-Giemsa (Hema 3, Fisher Scientific,
Tustin, CA), and 500 cells were counted per slide.
Flow Cytometry
Murine bone marrow or peripheral blood cells were collected at au-
topsy and suspended in phosphate-buffered saline (PBS). Human
bone marrow cells were obtained from Allcells (Berkeley, CA). Cells
were incubated with primary antibody for 30 min at 4C, followed by
a secondary goat anti-mouse antibody conjugated with phycoery-
thrin. The expression of G-CSF receptor on mouse bone marrow
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R&D Systems.
Hematopoietic Progenitor Cell Assays
23 104 bone marrow cells were plated in either 1 ml of methylcellu-
lose media MethoCult M3231 (Stem Cell Technologies) for mouse
bone marrow cells or MethoCult M4230 for human bone marrow
cells, supplemented with the indicated cytokines. Colonies were
counted on days 7–8. Recombinant cytokines were used at the fol-
lowing concentrations: G-CSF, 20 ng/ml; GM-CSF, 10 ng/ml; IL-3,
10 ng/ml; IL-6, 500 ng/ml; and stem cell factor, 100 ng/ml. To exam-
ine cell morphology and cell number, entire methylcellulose cultures
were harvested, washed extensively, counted, and evaluated by
Wright-Giemsa staining.
Retrovirus Infection
Retroviruses (pBABEpuroa9 [Young et al., 2001] or empty pBABE-
puro) were generated by transfection into the Phoenix-E virus pack-
aging cell line. Bone marrow cells were infected by incubation with
supernatants from infected Phoenix E cells.
Immunoblot Analysis and Coimmunoprecipitation
For immunoblotting, bone marrow cells were pelleted by centrifuga-
tion, resuspended in PBS, and treated for 10 min at 0C with 2 mM
diisopropyl fluorophosphate (DFP), a cell-permeable serine prote-
ase inhibitor, as described previously (Selsted et al., 1992). Cells
were lysed in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM
EDTA, 1 mM sodium ortho-vanadate, 50 mM NaF, 1% Triton
X-100, lysates were separated by SDS-PAGE, transferred to immo-
bilon, incubated with primary antibodies, and detected by ECL
(Amersham Pharmacia Biotech, Piscataway, NJ). CHO cell lines
were serum starved overnight, plated on Tnfn3RAA or collagen-
coated plates, stimulated with human G-CSF (20 ng/ml) for 5 and
30 min, and lysed as described above. BaF3 cells were grown in
RPMI medium with 10% fetal calf serum and 2 ng/ml murine re-
combinant interleukin 3. Cells were serum starved overnight, plated
on Tnfn3RAA and fibronectin-coated plates, and stimulated with hu-
man G-CSF (100 ng/ml) for 5 and 30 min at 37C. Cells were lysed in
10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 2 mM
Na3VO4, 1 tablet per 10 ml of solution of Complete Mini Protease
Inhibitor Cocktail tablets (Roche).
For coimmunoprecipitation, CHO or BaF3 cell lines were lysed on
ice for 30 min in an immunoprecipitation buffer: 20 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 10 mM EDTA, 1 mM sodium ortho-vanadate,
50 mM NaF, 1% CHAPS, 1 tablet per 10 ml of solution of Complete
Mini Protease Inhibitor Cocktail tablets (Roche). Lysates were clari-
fied by centrifugation at 16,000 3 g and incubated with protein
G-Sepharose coated with the a9b1 antibody, A9A1 at 4C overnight.
Beads were washed five times, and precipitated polypeptides were
extracted in Laemmli sample buffer, separated by SDS-PAGE under
reducing conditions, probed with a G-CSF receptor monoclonal
antibody (for CHO cells) or anti-HA (for BaF3 cells), and detected
by ECL.
Generation of Stable Cell Lines
Integrin a9-, a9a4-, a9a5- or a9(984X)-, a9(990X)-, and a9(1003X)-ex-
pressing CHO cells were transfected with human G-CSF receptor
cDNA (IMAGE: 5217305 clone from ATCC) in pSPORT6 vector at
a 5:1 ratio with pcDNA3.1.Hygro to induce hygromycin resistance.
Stable clones were obtained by hygromycin selection and cell sort-
ing by G-CSF receptor expression. BaF3 cells were infected by incu-
bation with a9-expressing retroviruses. Hemagglutinin (HA)-tagged
G-CSF receptor and mutated receptors were described previously
(Zhu et al., 2004). Integrin a9-expressing BaF3 cell were transfected
by electroporation. Stable cell lines were established by selection
with 500 mg/mL of G-418.
Cell Proliferation in Response to G-CSF
BaF3 cells proliferation was assayed as previously described (Zhu
et al., 2004). In brief, BaF3 cells were plated in Tnfn3RAA-coated
plates at a density of 1 3 105 cells/ml with 100 ng/ml human G-
CSF in 10% serum medium. Cell numbers were counted daily and
assessed for viability by trypan blue exclusion.Acknowledgments
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